Ionis Pharmaceuticals (IONS) Income from Continuing Operations (2009 - 2026)
Ionis Pharmaceuticals (IONS) recorded quarterly Income from Continuing Operations of 92528000.0 in Q1 2026, up 59.94% quarter-over-quarter from 230973000.0 in Q4 2025, and up 37.03% on a YoY basis from 67524282.65 in Q1 2025.
Ionis Pharmaceuticals (IONS) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 92528000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 37.03% year-over-year to 92528000.0; the TTM figure through Mar 2026 stood at 328556000.0 (up 28.37% YoY), while the FY2025 annual figure was 382966000.0, up 15.75% from the prior year.
- Income from Continuing Operations was 92528000.0 for Q1 2026 at Ionis Pharmaceuticals, up from 230973000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 123551000.0 in Q2 2025 to a low of 230973000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 92155647.06 across 5 years, with a median of 105012000.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations slumped 1033.67% in 2024, then jumped 286.45% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 52975000.0 in 2022, then jumped by 82.51% to 9263000.0 in 2023, then plunged by 1033.67% to 105012000.0 in 2024, then slumped by 119.95% to 230973000.0 in 2025, then jumped by 59.94% to 92528000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 92528000.0 (Q1 2026), 230973000.0 (Q4 2025), and 128606000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Ionis Pharmaceuticals | 12.23 Bn | 10.31 Bn | 243.11 Mn | -92.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.53 Mn |
| Dec 31, 2025 | -230.97 Mn |
| Sep 30, 2025 | -128.61 Mn |
| Jun 30, 2025 | 123.55 Mn |
| Mar 31, 2025 | -146.94 Mn |
| Dec 31, 2024 | -105.01 Mn |
| Sep 30, 2024 | -140.50 Mn |
| Jun 30, 2024 | -66.27 Mn |
| Mar 31, 2024 | -142.83 Mn |
| Dec 31, 2023 | -9.26 Mn |
| Sep 30, 2023 | -147.41 Mn |
| Jun 30, 2023 | -85.25 Mn |
| Mar 31, 2023 | -124.34 Mn |
| Dec 31, 2022 | -52.98 Mn |
| Sep 30, 2022 | -47.01 Mn |
| Jun 30, 2022 | -105.14 Mn |
| Mar 31, 2022 | -65.17 Mn |
| Dec 31, 2021 | 223.80 Mn |
| Sep 30, 2021 | -82.47 Mn |
| Jun 30, 2021 | -80.88 Mn |